Sai Parenterals Ltd

AI

Sai Parenterals Ltd

₹ 495 -1.27%
19 Nov - close price
About

Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]

Key Points

Business Profile[1][2]
Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.

  • Market Cap ₹ 2,189 Cr.
  • Current Price ₹ 495
  • High / Low ₹ 706 / 400
  • Stock P/E 85.2
  • Book Value ₹ 113
  • Dividend Yield 0.00 %
  • ROCE 7.03 %
  • ROE 5.80 %
  • Face Value ₹ 5.00

Pros

Cons

  • Stock is trading at 4.37 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 7.99% over last 3 years.
  • Company has high debtors of 183 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
19.20 47.78 38.48 56.79 52.78 52.91
16.17 37.43 34.51 43.56 39.43 43.79
Operating Profit 3.03 10.35 3.97 13.23 13.35 9.12
OPM % 15.78% 21.66% 10.32% 23.30% 25.29% 17.24%
1.24 0.63 0.75 0.12 3.41 3.59
Interest 1.76 1.47 2.12 3.42 3.57 2.49
Depreciation 1.32 1.34 1.60 1.53 1.36 1.52
Profit before tax 1.19 8.17 1.00 8.40 11.83 8.70
Tax % 30.25% 30.97% 64.00% -18.45% 24.94% 25.40%
0.83 5.64 0.36 9.95 8.88 6.49
EPS in Rs 0.22 1.53 0.10 2.25 2.01 1.47
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
97 114 124 162 201
79 92 97 134 161
Operating Profit 18 21 27 28 40
OPM % 18% 19% 22% 18% 20%
0 1 0 5 8
Interest 5 6 7 9 12
Depreciation 6 6 5 6 6
Profit before tax 7 10 14 19 30
Tax % 37% 30% 28% 11%
5 7 10 17 26
EPS in Rs 1.25 1.94 2.79 3.80 5.83
Dividend Payout % 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 19%
TTM: 31%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 55%
TTM: 63%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 8%
Last Year: 6%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Equity Capital 7 13 13 22 22
Reserves 24 65 78 465 478
69 71 72 133 101
34 45 52 184 34
Total Liabilities 134 194 215 804 636
44 41 40 43 49
CWIP 2 0 0 1 1
Investments 0 28 28 158 174
88 124 146 602 412
Total Assets 134 194 215 804 636

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Mar 2024 Mar 2025 Mar 2026
-21 -4 19 112
-17 -32 -13 -136
30 36 -6 433
Net Cash Flow -8 -1 -0 409
Free Cash Flow -38 -7 14 105
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -103% -6% 77% 413%

Ratios

Standalone / View Consolidated

Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 231 272 254 183
Inventory Days 83 97 130 208
Days Payable 140 156 160 89
Cash Conversion Cycle 174 213 224 302
Working Capital Days 27 70 53 -216
ROCE % 13% 14% 7%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025 Mar 2026
Group-wide capacity utilisation
%

Log in to view insights

Please log in to see hidden values.

Login
Cumulative product registrations in regulated markets
count
Dossiers approved/filed in the year
count
Dossiers developed in-house by R&D subsidiary (cumulative)
count
Dossiers under development (pipeline)
count
Group installed manufacturing capacity
million units
Number of complex products in portfolio
count
Pharmacy reach in Australia via long-term supply networks
count
Share of consolidated revenue from long-term supply contracts in regulated markets
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Mar 2026Jun 2026Sep 2026
51.16% 51.16% 51.16%
5.73% 4.03% 2.85%
12.86% 8.52% 7.83%
30.25% 36.29% 38.16%
No. of Shareholders 7,6879,31213,645

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents